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Available online 9 November 2016Background:Neuroimaging is essential for the diagnosis and prognosis of transient ischemic attack (TIA). The dis-
covery of a plasmatic biomarker related to neuroimagingﬁndings is of enormous interest because, despite its rel-
evance,magnetic resonance diffusionweighted imaging (DWI) is not always available in all hospitals that attend
to TIA patients.
Methods: Metabolomic analyses were performed by liquid chromatography coupled to mass spectrometry in
order to establish the metabolomic patterns of positive DWI, DWI patterns and acute ischemic lesion volumes.
We used these methods with an initial TIA cohort of 129 patients and validated them with a 2nd independent
cohort of 152 patients.
Findings: Positive DWIwas observed in 115 (40.9%) subjects and scattered pearls in one arterial territorywas the
most frequent lesion pattern (35.7%). The median acute ischemic lesion volume was 0.33 (0.15–1.90) cm3. We
detected a speciﬁc metabolomic proﬁle common to both cohorts for positive DWI (11 molecules including cre-
atinine, threoninyl-threonine, N-acetyl-glucosamine, lyso phosphatidic acid and cholesterol-related molecules)
and ischemic lesion volume (10molecules including lysophosphatidylcholine, hypoxanthine/threonate, and leu-
cines). Moreover lysophospholipids and creatinine clearly differed the subcortical DWI pattern from other pat-
terns.
Interpretation: There are speciﬁc metabolomic proﬁles associated with representative neuroimaging features in
TIA patients. Our ﬁndings could allow the development of serum biomarkers related to acute ischemic lesions
and speciﬁc acute ischemic patterns.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Diffusion magnetic resonance imaging
Metabolomics
TIA1. Introduction
Magnetic resonance diffusion weighted imaging (DWI) remains the
best neuroimaging technique to detect acute ischemia, above all since
the new tissular deﬁnition of transient ischemic attack (TIA) has be-
come essential in the evaluation of TIA patients (Easton et al., 2009). Ac-
cording to a recent meta-analysis, despite transient clinical symptoms,
one out of three patients with deﬁnite TIA has an acute DWI lesionnt of Neurology, Universitat de
, Clinical Neurosciences Group
. This is an open access article under(Brazzelli et al., 2014). Moreover, DWI has been shown to be an impor-
tant predictor of early stroke recurrence (Purroy et al., 2004) and it has
been proposed to add to clinical prognostic scales like ABCD2I (Giles et
al., 2011) and ABCD3I (Merwick et al., 2010). Furthermore, not only the
presence but also the patterns of DWI are important both for the etio-
logical classiﬁcation and for patient prognosis (Purroy et al., 2011).
However, despite the increased availability of magnetic resonance im-
aging (MRI) not all TIA patients undergo DWI. Therefore, the discovery
of a plasmatic biomarker related to neuroimaging ﬁndings is of enor-
mous interest.
Theuse ofmetabolomics on TIA patients has started a newera in bio-
marker discovering for clinical purpose (Jove et al., 2015a). Metabolo-
mics allows the study of the complete set of low-molecular-weight
intermediates (metabolites), which vary according to the pathologic
state of the cell, tissue, organ, or organism and are context-dependent
(Jove et al., 2014; Mauri-Capdevila et al., 2013).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to ﬁnd new biomarkers associated with the presence of acute DWI le-
sion and the volume and patterns of these lesions. As previously (Jove
et al., 2015a), results were validated in an independent cohort.
2. Methods
2.1. Subjects
This study was approved by the ethics committee of the Arnau de
Vilanova University Hospital. The main methodology has been previ-
ously described (Jove et al., 2015a). We prospectively recruited two in-
dependent cohorts of consecutive TIA patients whowere attended to by
a neurologist during the ﬁrst 24 h after the onset of symptoms. Both co-
horts shared the same methodology but were recruited at different
times (Fig. 1). We excluded 12 patients with contraindications to MRI
from the original study.We therefore analyzed 129patients from cohort
1 and 152 patients from cohort 2. TIA was deﬁned according to the clas-
sical deﬁnition as acute onset of focal cerebral or monocular symptoms
lasting b24 h and thought to be attributable to a brain ischemia (Anon,
1990). In order to avoid ethnic differences in the observedmetabolomic
proﬁles, all the patients included were Caucasian in origin. Patients
were classiﬁed etiologically according to the Trial of ORG 10172
(TOAST) (Adams et al., 1993). Undetermined territory included patients
without higher brain function disturbance such us aphasia,
hemianopsia, neglect, or vertebrobasilar symptoms. Vertebrobasilar
TIA was characterized by the following symptoms: bilateral or shifting
motor or sensory dysfunction, complete or partial loss of vision in hom-
onymous ﬁelds, dizziness, vertigo, or any combination thereof (Purroy
et al., 2011).
2.2. Neuroimaging Protocol
AMRI was acquired using a 1.5-T whole-body systemwith a 24-mT/
m gradient strength, 300 ms rise time, and an echo-planar–capableFig. 1. Patient increceiver equipped with a gradient overdrive (Philips Intera 1.5 T, MRI
scanner). The images obtained included axial T2-weighted turbo spin-
echo (TR/TE: 4800/120), T1-weighted spin-echo (TR/TE: 540/15), axial
turbo ﬂuid-attenuated inversion recovery (TR/TI/TE: 8000/2200/120),
and echo-planar diffusion images (TR/TE: 3900/95). The ﬁeld of view
was 230 mm and the matrix was 256 × 256 in all sequences. The DWI
were obtainedwith a single-shot spin-echo echo-planar pulse sequence
with diffusion gradient b values of 1000 s/mm2 along orthogonal axes
over 20 axial sections, using 6 mm thick sections, and an interslice gap
of 1 mm. Tissue abnormality (positive DWI) was deﬁned as areas of
high signal intensity on isotropic DWI reﬂecting an acute ischemic le-
sion. Patterns of DWI were determined according to a previous deﬁni-
tion (Purroy et al., 2011): DWI normality, scattered pearls in one
arterial territory (SPOT), multiple vascular territories, a single cortical
lesion in one vascular territory and a subcortical pattern. Two Neurora-
diologists blinded to clinical features established the presence and pat-
terns of DWI abnormalities. The interobserver agreement (kappa value)
is 1.0 for identifying positive DWI and 0.98 for identifying DWI patterns.
Furthermore, OsiriX V.4.0 imaging software (Rosset et al., 2004) was
used to calculate the total volume of DWI abnormality. We manually
outlined the respective abnormalities using the OsiriX closed polygon
tool, thereby creating a region of interest (ROI). ROIs in between the
segmented slices were interpolated automatically. The resulting DWI
abnormality volume was then determined.2.3. Metabolomic Analysis
For non-targeted metabolomic analysis, plasma samples were ob-
tained in the morning in order to avoid diurnal variations and metabo-
lites were extracted with methanol according to previously described
methods (Wikoff et al., 2008). Brieﬂy stated, 90 μl of cold methanol
(containing phenylalanine-C13 as an internal standard) were added to
30 μl of plasma, incubated for one hour at−20 °C and centrifuged for
three minutes at 12,000g. The supernatant was recovered, evaporatedlusion chart.
Table 1
Risk factors, clinical characteristics and neuroimaging data of both cohorts.
Variable Cohort 1
(n = 129)
Cohort 2
(n = 152)
Total
(n = 281)
p
Vascular risk factors
Age, mean (SD) 71.1 (10.4) 71.8 (11.2) 71.5 (10.8) 0.623
Male 83 (64.3) 91 (59.9) 174 (61.9) 0.442
Previous stroke 28 (21.7) 34 (22.5) 62 (22.1) 0.894
Hypertension 89 (69.0) 102 (67.1) 191 (68.0) 0.735
Coronary disease 17 (13.2) 20 (13.2) 37 (13.2) 0.996
Diabetes mellitus 40 (31.0) 44 (28.9) 84 (29.9) 0.707
Smoking 18 (14.0) 18 (11.8) 36 (12.8) 0.598
Hypercholesterolemia 49 (38.0) 59 (38.8) 108 (38.4) 0.886
Previous atrial
ﬁbrillation
17 (13.2) 15 (9.9) 32 (11.4) 0.384
Basal treatments
Aspirin 30 (23.3) 36 (23.8) 66 (23.6) 0.908
Clopidogrel 8 (6.2) 17 (11.3) 25 (8.9) 0.139
Anticoagulation 19 (14.7) 10 (6.6) 29 (10.4) 0.026
Statins 43 (33.6) 46 (30.5) 89 (31.9) 0.576
Renin-angiotensin
system blockers
64 (49.6) 71 (47.7) 135 (48.6) 0.744
Clinical features
Duration
b 10′ 12 (9.3) 16 (10.5) 28 (10.0) 0.925
10–59′ 49 (38.0) 56 (36.8) 105 (37.4)
1 h 68 (52.7) 80 (52.6) 148 (52.7)
Cluster TIA 35 (27.1) 33 (21.7) 68 (24.2) 0.290
Weakness 69 (53.5) 78 (51.3) 147 (52.3) 0.716
Isolated sensory
symptoms
12 (9.3) 13 (8.6) 25 (8.9) 0.826
Speech impairment 76 (58.9) 94 (62.3) 170 (60.7) 0.569
Vertebrobasilar 10 (7.8) 12 (7.9) 22 (7.9) 0.952
ABCD2, median (IQR) 5.2 (4.0–6.0) 5.1 (4.0–6.0) 5.1
(4.0–6.0)
0.753
Etiological subtypes
Large artery
atherosclerosis
32 (24.8) 29 (19.2) 61 (21.8) 0.509
Cardioembolism 23 (17.8) 35 (23.2) 58 (20.7)
Small-vessel disease 28 (21.7) 29 (19.2) 57 (20.4)
Undetermined cause 46 (35.7) 58 (38.4) 104 (37.1)
Neuroimaging features
DWI abnormality 59 (45.7) 56 (36.8) 115 (40.9) 0.145
Scattered pearls on one
territory
18 (14.0) 23 (15.4) 41 (14.7) 0.485
Multiple territories 4 (3.1) 3 (2.0) 7 (2.5)
Single cortical lesion 18 (14.0) 16 (10.7) 34 (12.2)
Subcortical lesion 19 (14.7) 14 (9.4) 33 (11.9)
DWI normality 70 (54.3) 93 (62.4) 163 (58.6)
DWI volume, mean (SD) 0.36
(0.15–1.91)
0.33
(0.15–2.45)
0.33
(0.15–1.90)
0.987
Percentages are shown in parentheses as appropriate.
DWI, diffusion-weighted images; TIA, transient ischaemic attacks; SD, standard deviation;
IQR, interquartile range.
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suspended in water containing 0.4% acetic acid/methanol (50/50).
We used an ultra-high pressure liquid chromatography (UHPLC)
schemewith an Agilent 1290 LC system coupled to an electrospray-ion-
ization quadruple time of ﬂight mass spectrometer (Q-TOF) 6520 in-
strument (Agilent Technologies, Barcelona, Spain). A column with a
particle size of 1.8 μmwas employed. The preliminary identiﬁcation of
differential metabolites was performed using the PCDL database from
Agilent (Agilent Technologies, Barcelona, Spain), which uses retention
times, exactmass and isotopedistribution in an standardized chromato-
graphic system as an orthogonal searchable parameter to complement
accuratemass data (AMRT approach) according to previously published
works (Sana et al., 2008). The version of the PCDL database used had re-
tention times and accurate mass data for 679 compounds.
2.4. Statistical Analysis
Statistics calculations were performed using the SPSS software ver-
sion 20 (SPSS, Chicago, IL) or the Stata 11 statistics package (StataCorp,
College Station, TX). Normal distribution of the variables was checked
by the Kolmogorov-Smirnoff test. Partial least discriminate analysis
(PLS-DA) was performed using Mass Molecular Proﬁler software
(Agilent Technologies, Barcelona, Spain). Brieﬂy stated, the number of
components chosen for PLS-DA was 4, and data were scaled using an
auto scaling algorithm. Validation of the model was achieved with a
N-fold validation type with 3 folds and 10 repeats as validation param-
eters. In all cases, signiﬁcance was considered for p b 0.05.
Statistical signiﬁcance for intergroup differences was assessed using
the Χ2 test for categorical variables and the Student's t-test, ANOVA test
and Mann-Whitney U test for continuous variables. Univariate analyses
were performed to detect variables associatedwith the presence of pos-
itive DWI and DWI patterns. Assuming that the ischemia volume deter-
mined on DWI could be considered to constitute a continuous variable,
we tested whether any circulating metabolite could be correlated with
it. Receiver operating characteristic (ROC) curves for metabolomic
datawere performedusing the ROCCET platform. ROC curveswere plot-
ted to predict the presence of positive DWI and DWI patterns.
3. Results
As we have published previously, we did not ﬁnd any statistically
signiﬁcant differences between the two cohorts based on vascular risk
factors, clinical characteristics and neuroimaging data (Jove et al.,
2015b).We observed DWI abnormalities in 115 (40.9%) patients.More-
over, SPOT pattern, present in 41 (35.7%) patients, was the most
frequent pattern (Table 1). Clinical features, vascular risk factors and eti-
ology varied signiﬁcantly among the different DWI patterns (Table 2).
Patients who had DWI abnormalities in multiple territories were older
than patients with other patterns. Motor weakness was more frequent
among subcortical lesion and multiple territories pattern. LAA was the
most frequent etiology among SPOT. Moreover, SPOT and multiple ter-
ritories pattern had higher volumes of DWI lesion. Themedian acute is-
chemic lesion volume was 0.33 (0.15–1.90) cm3.
3.1. Metabolomics and Positive DWI
Following metabolomic analyses of the discovery and validation co-
horts, a distinctive pattern of metabolites was found. As shown in the
heatmap (Fig. 2A), positive DWI exhibited a differential metabolomic
proﬁle in the discovery cohort. For PLSDAmodeling, a three-component
model with a high degree of accuracy (0.62, R2= 0.85) was obtained in
the discovery cohort (Fig. 2A). Similarly, the PLSDAmodel in the valida-
tion cohort also reached a high degree of accuracy (0.64, R2= 0.96, Fig.
2B). In addition to the separation offered by the PLSDA plot, whose axis
showed the integration of multiple compounds, we explored the capac-
ity of individual metabolites to explain separation between DWI andnon-DWI groups. The results (Fig. S1) revealed that several molecules
could differentiate these groups, with receiving operating characteristic
curves consistent in both cohorts. Univariate statistics showed that a
total of 87 molecular features in the discovery cohort were signiﬁcantly
different between positive DWI and normal DWI patients (Student's t-
test, p values between 6.98 E−5 and 0.05, supplemental dataset 1).
After applying the same approach to the validation cohort, 379molecu-
lar features showed signiﬁcant differences between these two groups
(Student's t-test, p values between 2.34 E−5 and 0.05, supplemental
dataset 1). When searching for common differential molecular features
shared by these two cohorts, 11 molecular features were found (Table
3). When we applied a database search using the PCDL software (inte-
grating exact masses, isotope distribution and retention time identity
with an identical LC/MS system) it was possible to propose several iden-
tities (Table 3), including creatinine, threoninyl-threonine, N-acetyl-
glucosamine, lysophosphatidic acid (LPA) and a cholesterol-related
molecule. Most differential compounds showed ROC areas (data not
shown) between 0.6 and 0.65, demonstrating that these molecules
could serve as potential biomarkers for acute ischemic lesions on DWI.
Table 2
Risk factors and clinical features by DWI patterns.
Variable All cases
(n = 281)
DWI normality
(n = 166)
Scattered pearls one territory
(n = 41)
Multiple territories
(n = 7)
Single cortical lesion
(n = 34)
Subcortical lesion
(n = 33)
p
Vascular risk factors
Age, mean (SD) 71.5 (10.8) 73.4 (9.9) 69.2 (11.3) 74.1 (5.5) 68.8 (13.8) 67.2 (10.2) 0.005
Male 174 (61.9) 95 (57.2) 32 (78.0) 5 (71.4) 20 (58.8) 22 (66.7) 0.165
Hypertension 191 (68.0) 118 (71.1) 27 (65.9) 4 (57.1) 20 (58.8) 22 (66.7) 0.687
Previous stroke 62 (22.1) 42 (25.3) 8 (19.5) 2 (28.6) 7 (20.6) 3 (9.1) 0.340
Diabetes mellitus 84 (29.9) 58 (34.9) 7 (17.1) 1 (14.3) 9 (26.5) 9 (27.3) 0.175
Coronary disease 37 (13.2) 23 (13.9) 6 (14.6) 1 (14.3) 6 (17.6) 1 (3.0) 0.448
Smoking 36 (12.8) 13 (7.8) 8 (19.5) 0 (0) 7 (20.6) 8 (24.2) 0.020
Hypercholesterolemia 108 (38.4) 64 (38.6) 17 (41.5) 5 (71.4) 18 (52.9) 4 (12.1) 0.003
Previous atrial ﬁbrillation 32 (11.4) 20 (12.3) 9 (22.0) 1 (14.3) 1 (2.9) 1 (3.0) 0.054
Clinical features
Cluster TIA 68 (24.2) 31 (19.0) 13 (31.7) 3 (42.9) 9 (26.5) 10 (30.3) 0.216
Speech impairment 170 (60.7) 103 (63.6) 20(48.8) 3 (42.9) 19 (55.9) 22 (66.7) 0.317
Motor weakness 147 (52.3) 68 (41.0) 27 (65.9) 5 (71.4) 21 (61.8) 26 (78.8) b0.001
Isolated sensory symptoms 25 (8.9) 20 (12.0) 1 (2.4) 1 (14.3) 0 (0) 3 (9.1) 0.096
Vertebrobasilar symptoms 22 (7.9) 11 (6.7) 4 (9.8) 1 (16.7) 3 (8.6) 3 (9.1) 0.867
Lacunar syndrome 105 (37.5) 61 (36.6) 15 (36.6) 0 (0) 9 (25.7) 20 (62.5) 0.007
Duration (n = 272) 0.087
b 10′ 28 (10.0) 22 (13.3) 3 (7.3) 1 (14.3) 0 (0) 2 (6.1)
10–59′ 105 (37.4) 58 (34.9) 16 (39.0) 2 (28.6) 20 (58.8) 9 (27.3)
1 h 148 (52.7) 86 (51.8) 22 (53.7) 4 (57.1) 14 (41.2) 22 (66.7)
ABCD2, median (IQR) 5.1 (4.0–6.0)
Etiological subtypes
Large artery disease 61 (21.8) 30 (18.1) 16 (39.0) 2 (28.6) 11 (32.4) 2 (6.1) b0.001
Cardioembolism 58 (20.7) 34 (20.5) 13 (31.7) 2 (28.6) 7 (20.6) 2 (6.1)
Small vessel disease 57 (20.4) 33 (19.9) 0 (0) (0) (0) 29 (87.9)
Undetermined 99 (35.2) 68 (41.0) 12 (29.3) 3 (42.9) 16 (47.1) 0 (0)
DWI volume, mean (SD) 0.33 (0.15–1.90) – 0.67 (0.28–2.99) 0.49 (0.04–1.19) 0.27 (0.07–7.17) 0.23 (0.17–0.68) 0.079
Percentages are shown in parentheses as appropriate.
DWI, diffusion-weighted images; TIA, transient ischaemic attacks; SD, standard deviation; IQR, interquartile range.
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In the discovery cohort, 43 molecules showed a signiﬁcant correla-
tion with acute ischemic lesion volume (Pearson correlation test, p
values between 3.12 E−07 and 0.05, Supplementary dataset 2). In the
validation cohort 211 molecules showed this feature (Pearson correla-
tion test, p values between 1.31 E−10 and 0.05, supplementary data
set 2). After searching for commonmolecules, a total of 7 different mol-
ecules were found including lysophosphatidylcholine, hypoxanthine/
threonate, and leucine (Table 4). Globally, these molecules showed a
signiﬁcant direct relationship with ischemia volume.3.3. Metabolomics and DWI Patterns
The results for the discovery cohort suggest speciﬁc metabolomic
proﬁles that cluster patients according to their DWI pattern. Subcortical
pattern patients were therefore clearly different from those with isolat-
ed cortical lesions and those with normal DWI according to a PLSDA
model with a moderate degree of accuracy (two-component model
0.503, R2 0.63, Fig. 3A). This was conﬁrmed by the analysis in the conﬁr-
mation cohort, where accuracy increased (two-component model 0.58,
R2 0.92, Fig. 3B). This supported the notion that, according to the
metabolomic proﬁles, the subcortical DWI pattern could be clearly dif-
fered fromother patterns, such us isolated cortical lesions andDWI neg-
ative patients. A random forest classiﬁcation scheme conﬁrmed these
ﬁndings, with subcortical patterns being classiﬁed with lower margin
of error (b0.05) in both cohorts.
In the case of univariate measurements, in the ﬁrst cohort a total of
81molecules were seen to be signiﬁcantly different from these patterns
(p values ranging between 2E−04 and 0.05, Supplemental dataset 3).
In the conﬁrmation cohort, 285 molecules differed across the DWI pat-
tern (p values between 5.94E−11 and 0.05, Supplemental dataset 3).
Conﬁrming the existence of potential biomarkers for the DWI pattern,
8 molecules were found to be common between these two cohorts(Table 5). These comprised lysophospholipids, as well as creatinine
and other unknown metabolites.
4. Discussion
To the best of our knowledge, this is the ﬁrst time that a metabolo-
mics approach has revealed potential biomarkers related to neuroimag-
ing ﬁndings after TIA. Previous data from different groups related
metabolomics data with neuroimaging in the context of bipolar disor-
der (McIntyre et al., 2014), multiple sclerosis (Vingara et al., 2013), de-
mentia such as Alzheimer's disease (Lista et al., 2015), schizophrenia
(Waddington, 2007), Parkinson disease (Ren et al., 2015) and even pe-
diatric cerebral infections (Pappa et al., 2015). We found a speciﬁc
metabolomic proﬁle related to acute ischemic lesions, volume and spe-
ciﬁc acute ischemic patterns. In a previous report, Bivard et al. (2014),
using magnetic resonance spectroscopy, discovered in ischemic stroke
patients with posttreatment hyperperfusion signs of increased gluta-
mate, N-acetylaspartate and lactate. These changes were related to in-
creased metabolism and potentially enhanced ulterior neuroplasticity.
In our case, positive DWI was linked to changes in several other metab-
olites, such as creatinine, N-acetyl-glucosaminylamine and LPA. Inter-
estingly, N-acetyl-glucosaminylamine, that is structurally related to N-
acetyl-glucosamine, and other similar molecules are modulators of im-
mune response (Srikrishna et al., 2001)when expressed at the endothe-
lial membrane. Assuming the important role of microglia and activated
neutrophils in brain ischemia response (Amantea et al., 2015), the pres-
ent ﬁndings could be in line with changes in expression and cleavage of
glycoprotein components. It should be noted that, one of the potential
markers for DWI positivity was a low level of LPA. These molecules,
and their signaling through their cognate receptor LPA1, have been im-
plicated in the generation of ischemia-related neuropathic pain (Halder
et al., 2013).Moreover, somemolecules from this family are also consid-
ered angiogenic factors (Ren et al., 2011; Binder et al., 2013). Therefore,
diminished levels may be associatedwith a lower capacity to withstand
hypoxia-induced apoptosis (Liu et al., 2009). Interestingly, other
Fig. 2. Association of DWI with differential metabolomic patterns. Upper panels: heatmap showing major metabolites differentiating plasma metabolomic proﬁles from DWI positive
versus non DWI positive patients, both in the discovery cohort (A) and in the validation cohort (B). A PLSDA model could be designed with a high accuracy, as shown in the lower
panels, both for the discovery cohort (A) and for the validation cohort (B).
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cular cerebral ischemia (Li et al., 2008). In this context, both activated
platelets and atheroma plaque are known sources of LPA (Haseruck et
al., 2004). The fact that LPA is a platelet activator and thrombotic
agent reveals the potential involvement of these molecules in cerebralTable 3
Molecular features differing between positive DWI and negative DWI patients.
Metabolite
Discover
Identiﬁcationa Mass
LysoPA(O-20:0)/5alpha-cholestane-3alpha,7alpha,12alpha,23,25-pentol 452.34
Unknown 1 218.01
Unknown 2 220.11
Creatinine 113.06
Threoninyl-Threonine/N-acetyl-b-glucosaminylamine/DiHDPA 362.25
Unknown 3 216.07
Unknown 4 154.97
Unknown 5 157.99
Unknown 6 146.07
RT, retention time; LysoPA, lysophosphatidic acid.
a Potential identities, based on retention time and exact mass are presented. When it is not
b After Student's t-test between positive DWI and negative DWI patients.changes linked to hypoxia. In order to explain whether the decreased
LPA observed in our DWI positive patients is a protective trait (in light
of its thrombogenic role) or a negative feature (based on the
antiapoptotic properties), it should be taken into account that we have
speciﬁcally found an increase in LPA (O-20:0). Furthermore, they cohort Validation cohort
RT (min) p valueb Mass RT (min) p valueb
5.98 0.011 452.34 6.21 0.001
0.29 0.028 218.01 0.21 0.007
9.13 0.006 220.11 9.13 0.008
0.38 0.050 113.06 0.38 0.012
11.67 0.009 362.25 11.94 0.012
0.43 0.007 216.08 0.56 0.013
0.14 0.023 154.97 0.28 0.013
0.30 0.039 157.99 0.23 0.017
0.41 0.019 146.07 0.39 0.038
possible to attribute only one identity, two or three potential identities are shown.
Table 4
Molecular features correlating with acute ischemic lesion volume.
Identiﬁcationa Discovery cohort Validation cohort
Mass RT (min) Pearson correlation coefﬁcientb p value Mass RT (min) Pearson correlation coefﬁcientb p value
LysoPC (22:6) 567.33 10.72 0.20 0.06 567.33 10.89 0.29 0.00
Hypoxanthine/threonate 136.04 0.78 0.20 0.06 136.04 0.78 0.23 0.01
Unknown 1 294.19 9.36 0.18 0.09 294.19 9.41 0.19 0.02
LysoPC (20:4)c 543.33 10.68 0.18 0.08 543.33 11.10 0.18 0.03
Unknown 2 760.03 0.34 -0.21 0.05 760.02 0.33 -0.16 0.04
Isoleucine/leucine/norleucine 131.09 0.56 0.30 0.00 131.09 0.55 0.16 0.05
Unknown 3 85.09 0.56 0.29 0.01 85.09 0.55 0.16 0.06
RT, retention time; LysoPC, lysophosphatidylcholine.
a Potential identities, based on retention time and exact mass are presented. When it is not possible to attribute only one identity, two or three potential identities are shown.
b Correlation coefﬁcient with ischemia volume.
c Note the difference in RT between the two cohorts. No peak with similar exact mass and isotope distribution was found closer to the ﬁrst retention time.
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side chain (Haseruck et al., 2004).
As in our previous work (Jove et al., 2015b), speciﬁc patterns of
LysoPC were again relevant. LysoPC (22:6) and LysoPC (20:4), that
were previously related to LAA and stroke recurrence respectively,
were now associated with lesion volume. Furthermore, LysoPC (16:0),
that was low in those TIA patients who suffered a subsequent stroke,
was now related to SPOT and cortical patterns. All these associations
made sense because SPOT and cortical patterns which are overrepre-
sented in LAA patients (Purroy et al., 2011) had the biggest lesion
volume.
Ourwork shows some inherent limitations. The fact that the patients
were heterogeneous in fasting time, aswell as differences in gender, eti-
ology, pharmacological treatment or age, to name a few, could hinder
some potential biomarkers. Moreover, plasma metabolites levels could
be inﬂuenced bymany factors such as diet, medications, age and clinical
variables (Mauri-Capdevila et al., 2013). However, the use of two co-
horts allows overcoming these potential limitations, increasing the ro-
bustness of the resulting data (Jove et al., 2015a; Shi et al., 2004). A
further limitation of the present work is the fact that many molecules
where not identiﬁed, although it is a common circumstance for these
kind of analyses (Vaniya and Fiehn, 2015). However, the use of orthog-
onal approaches, such as the use of retention time in standardized chro-
matographic systems, exact mass and isotope pattern, could help to
overcome this limitation, leading to the formulation of potentialFig. 3. Imaging patterns of ischemia are associated with differential metabolomic proﬁles.
metabolomic proﬁles, both for the discovery cohort (A) and for the validation cohort (B).biomarkers (Sana et al., 2008). Additionally, there is an important step
left to be done in order to implement our results in the everyday clinical
practice. We have to recognize that metabolomic analysis is too expen-
sive and requires extensive temporal and personal resources. So once
potential biomarkers are identiﬁed, economic and fast techniques, ame-
nable tomost clinical laboratories, need to be developed to detect them.
Finally, we included only TIA patients even we knew that the diagnosis
of transient ischemia could sometimes be problematic as many condi-
tions mimic this situation. Further research should be done in big tis-
sue-deﬁned ischemia cohorts to conﬁrm our results.
Globally, our data support the existence of metabolic patterns asso-
ciated with neuroimaging features after transient brain ischemia that
could allow the development of serum biomarkers related to acute is-
chemic lesions and speciﬁc acute ischemic patterns.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.11.010.
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Fund (PI 14/01115) “A way to build Europe”.PLSDA model showing association of different ischemia imaging patterns with speciﬁc
Table 5
Molecules differing across DWI patterns.
Identiﬁcationa Discovery cohort Conﬁrmation cohort
Mass RT
(min)
p
valueb
Fisher's LSDc (n of patients) Mass RT
(min)
p
valueb
Fisher's LSDc (n of patients)
LysoPC(16:0)/LysoPE(19:0) 495.33 10.77 0.02 Normal DWI (70)- Isolated cortical lesion
(18); SPOT(18) - Isolated cortical lesion
(18); Subcortical (19) - Isolated cortical
lesion (18)
495.33 10.78 0.00 Isolated cortical lesion (16) - SPOT
(23); Normal DWI (83) - SPOT (23)
2-Oxo-4-methylthiobutanoic acid 148.02 9.69 0.04 Normal DWI(70) - Isolated cortical lesion
(18); Subcortical - Isolated cortical lesion
(18)
148.01 9.68 0.00 SPOT (23) - Isolated cortical lesion (16);
SPOT (23) - Normal DWI (83)
Creatinine 113.06 0.38 0.00 Isolated cortical lesion (18) - Multiples
territories (4); Normal DWI(70) - Isolated
cortical lesion (18); Subcortical (19) -
Isolated cortical lesion (18); Normal
DWI(70) - Multiples territories (4); Scattered
one territory - Multiples territories (4);
Subcortical (19) - Multiples territories (4)
113.06 0.38 0.01 Isolated cortical lesion (16) - SPOT (23);
Normal DWI (83) - SPOT (23);
Subcortical (14) - SPOT (23)
Pyroglutamic
acid/N-Acryloylglycine/Pyrroline
hydroxycarboxylic
acid/4-Oxoprolined
129.04 0.65 0.02 Isolated cortical lesion (18) – SPOT (18);
Normal DWI (70)- SPOT(18); Subcortical
(19) – SPOT (18)
129.04 0.38 0.01 Isolated cortical lesion (16) - SPOT
(23); Normal DWI (83) – SPOT (23)
Unknown1 760.03 0.34 0.05 Normal DWI (70)- Isolated cortical lesion
(18); SPOT (18) - Isolated cortical lesion
(18); Subcortical (19) - Isolated cortical
lesion (18)
760.02 0.33 0.02 Normal DWI (83) - Isolated cortical
lesion (16); Subcortical (14) - Isolated
cortical lesion (16); Normal DWI (83) -
SPOT (23); Subcortical (14) - SPOT (23)
Unknown2 825.97 0.35 0.02 SPOT(18) - Normal DWI(70); Subcortical
(19) - Normal DWI (70)
825.98 0.33 0.03 SPOT (23) - Isolated cortical lesion (16);
SPOT (23) - Normal DWI (83)
Eicosatrienoic acid 306.26 12.17 0.05 Isolated cortical lesion (18)- Normal
DWI(70); Isolated cortical lesion (18) -
Subcortical (19); SPOT(18) - Normal
DWI(70); SPOT (18) – Subcortical (19)
306.26 12.13 0.03 SPOT (23) - Isolated cortical lesion (16);
SPOT (23) - Normal DWI (83)
RT, retention time; LysoPC, lysophosphatidylcholine; SPOT, scattered pearls in one arterial territory; DWI, diffusion-weighted images; LysoPE, lysophosphatidylethanolamine.
a Potential identities, based on retention time and exact mass are presented. When it is not possible to attribute only one identity, two or three potential identities are shown.
b After ANOVA considering different DWI patterns.
c Post-hoc analyses using Fisher's Least Signiﬁcant Difference test, indicating signiﬁcantly different groups separated by semicolon. Identical differences found in both cohorts are
marked by a bold font.
d Note the difference in RT between the two cohorts. No peak with similar exact mass and isotope distribution was found closer to the ﬁrst retention time.
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